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Background
Subcutaneous injections of anti-CD20 antibodies may offer benefits to both patients and the healthcare system for treatment of B-cell malignancies.
Design and Methods
A pilot study was undertaken to evaluate the potential for subcutaneous dosing 
Introduction
Following the successful application of the chimeric anti-CD20 monoclonal antibody (MAb), rituximab, in the therapy of non-Hodgkin lymphoma (NHL) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] and autoimmune disorders, [11] [12] [13] [14] second-generation anti-CD20 antibodies have been developed to increase efficacy, decrease toxicity (primarily infusion reactions) or immunogenicity, and allow more rapid administration. [15] [16] [17] [18] [19] [20] [21] [22] Veltuzumab (hA20) is a humanized, anti-CD20 MAb with similarities as well as structural and functional differences from rituximab. [23] [24] [25] [26] In the complementaritydetermining regions, veltuzumab differs from rituximab by only one amino acid, but has completely different framework regions. Veltuzumab showed antiproliferative, apoptotic, and antibody-dependent cellular cytotoxicity effects in vitro similar to rituximab, but with other qualitative differences, including slower off-rates and increased complement-dependent cytotoxicity in several human lymphoma cell lines. In mice bearing human lymphoma xenografts, low doses of veltuzumab controlled tumor growth, even producing a number of cures.
In the initial NHL clinical study, 82 patients received veltuzumab intravenously, given once weekly for 4 weeks. 27 That study demonstrated the safety of veltuzumab at doses of up to twice the standard rituximab dose of 375 mg/m 2 . Interestingly, objective responses, including complete responses, occurred at doses as low as 80-120 mg/m 2 weekly x 4. Therefore, veltuzumab was reformulated in more concentrated form (approximately 80 mg/mL) and this pilot study was undertaken to evaluate the feasibility for delivery of low doses by subcutaneous (SC) injection. Anticipating that a fluid volume of 2 mL or less would be able to be administered by SC injection, 3 doses were selected for evaluation, with 80 and 160 mg doses to be delivered by one injection, and 320 mg doses by two separate injections. All patients received a total of 4 doses of veltuzumab, but with a two week dosing interval to allow for anticipated slow
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release into the blood. This initial study also focused on exclusively on patients with indolent lymphomas for whom the convenience of this route of administration may be of particular benefit.
Design and Methods
Design
In this open-label, multicenter phase I study, patients with indolent NHL received 80, 160 or 320 mg SC veltuzumab administered every other week for a total of 4 administrations. The primary objectives were to evaluate the safety, tolerance and immunogenicity of veltuzumab with this route of administration and dosing schedule. Secondary objectives were to obtain preliminary evidence of efficacy and to assess pharmacokinetics and pharmacodynamics. Neither steroids nor other premedications were routinely required unless clinically indicated. Initially, a standard dose escalation design was used, with escalation continuing as long as 0 of 3 or 1 of 6 patients encountered dose limiting toxicity. The study concluded after several additional patients were then entered to provide more experience with 160-and 320-mg doses. 
Patients
Assessments
NHL subtypes were determined for each patient by WHO classification 28 and FLIPI prognostic scores were assigned for follicular lymphomas. 
Statistical analysis
Response rates were summarized using descriptive statistics. Progression-free survival (PFS) was calculated from first injection to disease progression, death, or last contact, whichever occurred earliest. Duration of response (DR) was calculated from the onset of an objective response (OR; ie, CR, CRu, or PR) to the same events. The Kaplan-Meier method was used to generate PFS and DR survival curves and the corresponding confidence intervals for the estimated medians.
Results
Patient Enrollment
Seventeen patients (14 patients Demographics and patient characteristics are summarized in Table 1 .
Study drug administration
Patients were treated at all 3 dose levels with no occurrences of dose limiting toxicity. All patients completed treatment, receiving four SC doses administered every two weeks at their assigned dose level (Table 1) .
Treatment responses
Across all histologies, the objective response (CR + CRu + PR) rate was 47.1% with other histologies, two with high circulating B-cell levels did not achieve an objective response, while the third patient with small lymphocytic lymphoma (SLL) had a CR continuing 72 weeks after the first SC injection. Table 2 lists response rates by histology, dose level, and other factors.
Adverse events
Thirteen patients had one or more AEs during the study (Supplementary Table   S1 , online only). Events occurring in more than one patient were injection site reaction (35%), pain in extremity (24%), upper respiratory tract infection (18%), nausea (18%), chills (12%), and dyspnea (12%). One patient had an isolated pulmonary nodule on CT prior to study entry which was confirmed as a squamous cell carcinoma while on study. Otherwise, there were no serious events (SAEs) and all other AEs were either mild or moderate events (ie, Grade 1 or 2 toxicity). Most events were injection reactions, which occurred in 9 patients [8 with localized pain or tenderness (n = 7) or redness (n= 6) at the injection site; 5 had chills or nausea (n=2 each), thoracic pain, general aching, headache, swollen tongue or rash (n=1 each)]; these were predominantly only mild (Grade 1) transient events that typically resolved spontaneously or otherwise with symptomatic topical or oral medication (no steroids were given).
Four patients had infections, but these were all mild (Grade 1) events, involved the upper respiratory tract (n=3) or sinuses (n=1), and resolved with oral medications.
Safety laboratories
Blood samples for hematology and serum chemistries were obtained before each injection, 4 and 12 weeks after the last injection, and every 3 months during follow-up. No abnormal pattern of changes occurred (Supplementary Tables S2   and S3 , online only), and there were no cases of delayed neutropenia (including 10 patients monitored for 6 months, and 6 patients for one year).
Pharmacokinetics
One patient did not undergo the schedule of serum sampling required for PK analysis and another patient with splenic marginal zone lymphoma (MZL) and extremely elevated peripheral blood B-cell levels had unmeasurable serum levels of veltuzumab (< 0.5 µg/mL) at all time points. PK was analyzed for the other 15 patients, all of whom had measurable veltuzumab levels over the course of treatment. Figure 1 summarizes the mean serum levels for each dose group at scheduled times for serum sampling, whereas Table 3 summarizes PK parameters after the fourth and final injection.
Hematologic changes
Two patients in this study had leukemic involvement with elevated circulating B- 
Immunogenicity (HAHA)
Serum samples were obtained at baseline, prior to 3 rd injection, then 4 and 12 weeks after 4 th injection and analyzed for HAHA by ELISA. All samples were negative (<50 ng/mL).
Discussion
By avoiding lengthy IV administration and the need for dedicated infusion suites and staff, subcutaneous injections of veltuzumab for treatment of B-cell malignancies may offer benefits to both patients and the healthcare system. (40% OR, 11% CR). 31 Two patients with bulky disease (both with FL, one dosed at 160 mg and the other at 80 mg) did not achieve an objective response, suggesting that higher doses or more frequent dosing may be required for patients with higher tumor burdens. Only 5 FL patients in the present study had a high risk of poor outcome (3-5 FLIPI scores) and 2 achieved partial responses to therapy; further experience will be needed to evaluate the utility of SC injections in this important group.
Three patients enrolled in this study had non-FL histologies. One with SLL achieved a CR, currently ongoing now 72 weeks after treatment. The other two patients (one SLL, one MZL) entered with high levels of circulating B cells and failed to achieve an objective response. We have reported that in patients with chronic lymphocytic leukemia (CLL), the same SC doses and dosing schedule of veltuzumab used here also failed to achieve meaningful clinical benefit, but had evidence of pharmacological activity with transient decreases in the high levels of circulating leukemic B cells. 32 For SC injections, more frequent or extended dosing or combination therapy with other agents will likely be required to overcome the higher antigen burden in these settings, consistent with the experience of other anti-CD20 antibodies which are given intravenously at much higher doses for patients with CLL. 21 Compared to the peak concentrations seen immediately after IV infusions, veltuzumab was released slowly into the blood after SC injections, achieving peak levels only after several days. In spite of the low doses administered here on an every other week dosing schedule, sustained serum levels of veltuzumab were achieved across the treatment period and were still measurable for 4 to 8 weeks afterwards. As expected with this slower release, the mean maximum antibody serum levels of 19, 25 and 63 µg/mL obtained at the 80, 160 and 320 mg x 4 doses, respectively, are generally lower than the maximum values that occurred with bolus delivery of higher IV veltuzumab doses. 27 Nonetheless, this SC dosing achieved serum levels that are close to or exceed the 25-µg/mL value associated with maintained efficacy of rituximab, 33 thus supporting the clinical activity that was observed at all dose levels in this study. Veltuzumab was pharmacologically active when given by SC injection. Similar to what was observed with higher IV doses of veltuzumab, 27 B-cell depletion occurred after the first administration, even at a dose of only 80 mg. Interestingly, the mean terminal half-lives for the three SC dose levels studied here were similar following the last administration (12.4 to 13.9 days) and also generally comparable to halflives previously reported with higher doses of veltuzumab given intravenously (13.3 to 19.7 days). 27 While these pharmacokinetic and pharmacodynamic findings generally support the use of SC dosing, serum levels of veltuzumab were very low or unmeasurable for two patients with leukemic involvement (one splenic MZL, one SLL), whose elevated peripheral B-cell levels decreased, but
were not depleted with 160-mg doses and in an additional patient with FL treated at 80 mg who had extensive adenopathy (including >10 cm masses). These results suggest that while the SC treatment schedule in this study may be sufficient to cover the antigen sink in most indolent NHL patients, those with greater tumor burden will likely require higher doses or more frequent dosing to overcome leukemic involvement or extensive adenopathy. As mentioned, this is particularly relevant in CLL patients.
More than 10 years after the initial approval of the first anti-CD20
antibody, rituximab, the relationship between anti-CD20 dose levels and treatment response remains to be clarified. [33] [34] [35] Most second-generation antibodies have pursued doses close to or higher than the 375 mg/m 2 dose typically given with rituximab. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] However, a proper dose-ranging study was never reported even though the initial studies of rituximab in NHL had demonstrated that treatment responses also could occur at much lower doses. 36, 37 In other diseases like immune thrombocytopenia (ITP), with presumably less antigen burden, 100-mg rituximab doses have shown activity, 38 and even in the face of the high leukemic burden in CLL, frequently repeated 20-mg SC rituximab doses given to four patients were shown to be active in one. 39 Thus, it is not surprising that low doses of veltuzumab could also be effective in NHL, as shown previously with intravenous administrations 27 or here with subcutaneous injections. In addition, SC injections of veltuzumab at the same low doses used here were also effective in ITP with doses given only twice, 2-weeks apart, 40 and were capable of transiently decreasing the high levels of circulating leukemic cells in CLL, when given only four times with the same dosing schedule used in the present study. 32 In conclusion, this study shows that SC injections of low-dose veltuzumab given every two weeks for a total of four administrations are well tolerated, achieving slow but effective delivery into the blood that is pharmacologically 
